European Hematology Association Hybrid Congress
EHA 2025
- Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML
- Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with R/R Multiple Myeloma
- Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel’s Potential for Long-Term Remission in R/R B-ALL
- BioInvent Announces Updated Ph 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the treatment of non-Hodgkin’s lymphoma
- Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in R/R Acute Leukemia
- Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader
- Bristol Myers Squibb Presents First Data from the MZL Cohort of the Transcend FL Trial showing Deep & Durable Responses with Breyanzi (lisocabtagene maraleucel)
- Early results from Johnson & Johnson’s trispecific antibody JNJ-79635322 show promising response in heavily pretreated multiple myeloma patients
- Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML
- Faron Pharmaceuticals presents updated Ph 2 data from BEXMAB Study
- Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with R/R DLBCL Eligible for ASCT
- GSK data at EHA showcase latest research and innovation across the oncology portfolio
- Investigational combination of TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
- Johnson & Johnson’s dual-targeting CAR T-cell therapy JNJ-90014496 shows encouraging first results in large B-cell lymphoma
- Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML
- Molecular Partners presents positive data from ongoing Ph 1/2a trial of MP0533 in AML
- Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
- New results for Johnson & Johnson’s bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for AML
- Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with R/R CLL and WM
- Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505
- Significant efficacy benefit of IMBRUVICA® (ibrutinib) + venetoclax vs acalabrutinib + venetoclax in 1L CLL suggested by indirect treatment comparison
- Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial
